Quillichew Er

Do not substitute for other methylphenidate products on a mg-per-mg basis. High potential for abuse, misuse, and addiction; assess patient’s risk before prescribing. Assess for presence of cardiac disease before initiation. Avoid in known structural cardiac abnormalities, cardiomyopathy, serious arrhythmias, coronary artery disease, or other cardiac disease. Pre-existing psychotic disorder. Depression. Bipolar disorder. Screen for risk factors in developing a manic episode prior to initiating. Consider discontinuing if new psychotic or manic symptoms occur. Peripheral vasculopathy, including Raynaud's phenomenon; monitor for digital changes. Risk for acute angle glaucoma. History of increased IOP or open angle glaucoma; monitor closely. Assess family history and evaluate for tics or Tourette’s syndrome before initiating; monitor for emergence or worsening, and discontinue if clinically appropriate. Monitor BP, HR, growth in children. Reduce dose or discontinue if paradoxical aggravation of symptoms occurs. Reevaluate periodically. Phenylketonuria. Neonates. Pregnancy. Nursing mothers: monitor infants.